Abstract
The aim of highly-active antiretroviral therapy (HAART) is to suppress HIV-1 viral load (VL) to undetectable levels. All patients on HAART should have a VL measured at regular intervals in order to monitor the success of therapy. In October 2006 the Newcastle Health Protection Agency (HPA) laboratory replaced the Roche COBAS HIV-1 Ampliprep Amplicor Monitor (CAP/CA) assay with the more-sensitive Roche COBAS Ampliprep Taqman HIV-1 (CAP/CTM1) assay. Both locally and internationally the introduction of the CAP/CTM1 assay was associated with a significant unexplained increase in the detection of low level HIV-1 viraemia (VL 50 to 1000 copies/ml).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
